Former Pfizer Executive and Physician Leader Joins CrossBridge As Chief Medical Officer - CrossBridge
15615
post-template-default,single,single-post,postid-15615,single-format-standard,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

Former Pfizer Executive and Physician Leader Joins CrossBridge As Chief Medical Officer

Former Pfizer Executive and Physician Leader Joins CrossBridge As Chief Medical Officer

Wayne, PA, January 21, 2019 – In rounding out its C-suite, early-stage healthcare technology company, CrossBridge has tapped Dr. Bruce Freundlich to become its Chief Medical Officer.

Confirming Dr. Freundlich’s appointment, Bill Conlan, CrossBridge’s Founder and CEO, had this to say: “Dr. Freundlich has an acute grasp of our mission and the collaboration our SaaS solution can bring about between providers and payers to improve outcomes, lower the cost  of care and facilitate the transition to value-based payments with respect to chronic diseases.  Our initial targets will be inflammatory diseases such as rheumatoid arthritis and crohns.”

In addition to serving as Vice President, Medical at Antares Pharmaceuticals, Dr. Freundlich was Vice President Inflammation and Vice President, Global Medical Affairs at Pfizer Pharmaceuticals.  While at Pfizer, one of his responsibilities was the post-marketing Embrel trials.

Dr. Freundlich is skilled in clinical research and medical affairs, with expertise in Rheumatology, Dermatology, Endocrinology and Neuro-psychiatry.  He served as Chief of Clinical Rheumatology at the University of Pennsylvania for more than six years.

About CrossBridge

CrossBridge is an early-stage healthcare technology company, specializing in Software as a Service (SaaS) solutions that enable payers and healthcare providers to strive collaboratively for the best outcomes at the lowest cost for chronic diseases – all while advancing the transition from fee-for-service to Value Based Payments (VBP).

 

No Comments

Post A Comment